Social Behavior: Clinical Trials

69 trials for Social Behavior, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

69 completed. 69 Phase 2, 11 Phase 1, 5 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 269Completed 69
Phase 111Completed 11
Phase 35Completed 5

Follow Social Behavior: new trials by email Literature Review of Social Behavior trials Research Report on Social Behavior

Trials (filtered) newest first · largest first

All 69 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Delayed Supine Position Post-Spinal Compared With Immediate Supine Position in Geriatric Patients
2 minutes setting post spinal anesthesia, immediate supine position - we Study the Effect of Keeping the Patient Supine 2 Minutes After Spinal Anesthesia in Geriatric Groups
Phase 2CompletedSohar Hospital902025-01-012026-04-09
Result of tDCS in ASD Children With Comorbidities Like PANDAS, Rare Genetic Diseases or Autoimmune Disorders
tDCS or Transcranial Direct Current Stimulation, Risperidone, Sham tDCS - Attention, Visual Perceptual Weakness
Phase 1 / Phase 2CompletedSpanish Foundation for Neurometrics Development1802024-04-012026-09-10
PRISM Race and Communication Pilot RCT
Promoting Resilience in Stress Management (PRISM) - Discrimination, Racial, Communication
Phase 1 / Phase 2CompletedUniversity of Washington282023-07-192026-04-30
Arthritis Ease Study
Virtual Reality Nature scene plus heart rate variability biofeedback phone application - Knee Osteoarthritis, Chronic Pain
Phase 1 / Phase 2CompletedArizona State University362022-09-152024-09-23
Low-intensity Stepped Care for Internalizing Distress
Common Elements Toolbox, Doing What Matters in Times of Stress: An Illustrated Guide, Guided self-help - Depression, Anxiety
Phase 2CompletedIndiana University2752022-06-292024-05-07
SMART Trial: Intrapersonal and Interpersonal Stigma Reduction
Intrapersonal Stigma Reduction, Interpersonal Stigma Reduction - Stigma, Social, Opioid Use
Phase 2CompletedUniversity of Tennessee712021-03-082023-03-09
Propranolol for Challenging Behaviors in Autism
Propranolol - Autism Spectrum Disorder, Developmental Disability
Phase 2CompletedRutgers, The State University of New Jersey82021-02-112025-06-04
A Study to Evaluate the Safety and Efficacy of Dual Costimulation Blockade With VIB4920 and Belatacept for Prophylaxis of Allograft Rejection in Adults Receiving a Kidney Transplant
Belatacept, VIB4920, Thymoglobulin - Allografts, Rejection; Transplant, Kidney
Phase 2CompletedAmgen252019-10-302024-12-27
Arbaclofen in Children and Adolescents With ASD
Arbaclofen, Placebo - Autism Spectrum Disorder
Phase 2CompletedCelso Arango, MD, PhD1242019-09-192023-02-08
Clinical, Neurocognitive, and Emotional Effects of Psilocybin in Depressed Patients - Proof of Concept
Psilocybine oral capsule, Placebo oral capsule - Depressive Disorder, Major
Phase 2CompletedUniversity of Zurich552019-03-112022-04-29
Peer Support Intervention to Mitigate Social Isolation and Stigma of Adolescent Motherhood in Zimbabwe
Young Women of Today - Mental Health Disorder, Social Isolation
Phase 2CompletedWest Chester University of Pennsylvania1832018-10-012022-02-15
Rapid Agitation Control With Ketamine in the Emergency Department
Ketalar, Midazolam injection, Haloperidol - Violent Aggressive Behavior, Ketamine
Phase 2CompletedDavid Barbic812018-05-292020-11-30
Comparison of the Cognitive and Motor Effects of Treatment Between an Immediate- and Extended-release Tacrolimus (EnvarsusĀ® XR) Based Immunosuppression Regimen in Kidney Transplant Recipients
immediate-release tacrolimus, extended release tacrolimus - Kidney Transplant Failure and Rejection
Phase 1 / Phase 2CompletedUniversity of Minnesota182018-05-082021-04-15
Clazakizumab in Highly-HLA Sensitized Patients Awaiting Renal Transplant
Clazakizumab - Kidney Failure, Chronic, End-Stage Renal Disease
Phase 1 / Phase 2CompletedStanley Jordan, MD202018-02-272026-10-30
Oxytocin, Alcohol Craving, and Intimate Partner Aggression
Oxytocin, Placebo - Alcohol Use
Phase 2CompletedMedical University of South Carolina2002017-07-012022-05-09
Study to Assess the Efficacy, Safety, and Tolerability of AVP-786 for the Treatment of Neurobehavioral Disinhibition Including Aggression, Agitation, and Irritability in Participants With Traumatic Brain Injury
Placebo, AVP-786-28, AVP-786-42.63 - Neurobehavioral Disinhibition
Phase 2CompletedOtsuka Pharmaceutical Development & Commercialization, Inc.1682017-05-302025-10-29
Oxytocin and Social Cognitive Skills Groups
Oxytocin, Social Cognitive Skills Training, Facilitated Play Therapy - Autism Spectrum Disorder
Phase 2CompletedRush University Medical Center402016-06-152024-04-05
Honest Open Proud for Adolescents With Mental Illness
Honest Open Proud (HOP) - Secrecy Versus Disclosure Among Adolescents With Mental Illness
Phase 2CompletedUniversity of Ulm1002016-05-012017-05-09
Omega-3 Supplementation and Behavior Problems
Omega-3 supplemented drink, Smartfish - Aggression, Antisocial Behavior
Phase 2 / Phase 3CompletedDr. Annis Fung3242015-02-012018-07-18
Differences in Schizophrenia With One-month and 3-month Paliperidone Palmitate Treatment
Paliperidone Palmitate 156 MG/ML Prefilled Syringe [Invega], Paliperidone Palmitate 546 MG Intramuscular Suspension, Extended Release [INVEGA TRINZA] - Schizophrenics
Phase 1 / Phase 2CompletedCalo Psychiatric Center722015-01-012021-02-15

Showing 20 of 69. Sign in to see all of them.

Narrower conditions

Aggression (28)  ·  Rejection, Psychology (15)  ·  Alzheimer Disease (5)  ·  Emotional Regulation (5)  ·  Psychomotor Agitation (5)  ·  Depression (4)  ·  Mental Disorders (4)  ·  Psychological Well-Being (4)  ·  Social Skills (4)  ·  Asperger Syndrome (3)  ·  Autism Spectrum Disorder (3)  ·  Autistic Disorder (3)  ·  Child Development Disorders, Pervasive (3)  ·  Liver Diseases (3)  ·  Lymphoma, Non-Hodgkin (3)

Broader conditions

Behavior (69)  ·  Behavioral Symptoms (32)  ·  Aberrant Motor Behavior in Dementia (28)  ·  Mental Disorders (26)  ·  Pathological Conditions, Signs and Symptoms (14)  ·  Nervous System Diseases (8)  ·  Neurologic Manifestations (8)  ·  Neurodevelopmental Disorders (7)  ·  Pathologic Processes (7)  ·  Signs and Symptoms (7)  ·  Urogenital Diseases (7)  ·  Brain Diseases (6)  ·  Central Nervous System Diseases (6)  ·  Disease Attributes (6)

Interventions

Mycophenolic Acid (4)  ·  Adrenal Cortex Hormones (3)  ·  Alemtuzumab (3)  ·  Tacrolimus (3)  ·  Abatacept (2)  ·  Aripiprazole (2)  ·  Citalopram (2)  ·  Cyclosporine (2)  ·  Health (2)  ·  Liver Transplantation (2)  ·  Luteinizing Hormone, beta Subunit (2)  ·  Methylprednisolone (2)  ·  Oxytocin (2)  ·  Prednisone (2)  ·  Psychotherapy (2)

Sponsors

Novartis Pharmaceuticals (4)  ·  Arizona State University (2)  ·  Indiana University (2)  ·  Merck KGaA, Darmstadt, Germany (2)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (2)  ·  University of Konstanz (2)  ·  University of Pittsburgh (2)  ·  Amgen (1)  ·  Avanir Pharmaceuticals (1)  ·  Azevan Pharmaceuticals (1)  ·  Boston University (1)  ·  Bristol-Myers Squibb (1)  ·  Calo Psychiatric Center (1)  ·  Cambridge Health Alliance (1)  ·  Celso Arango, MD, PhD (1)

Countries

United States (49)  ·  Canada (7)  ·  Spain (6)  ·  Germany (5)  ·  United Kingdom (5)  ·  France (4)  ·  Belgium (2)  ·  Burundi (2)  ·  Switzerland (2)  ·  Australia (1)  ·  Austria (1)  ·  China (1)  ·  Finland (1)  ·  Italy (1)  ·  Jordan (1)

Top investigators

Abraham Shaked, MD, PhD (1)  ·  Amy Birney, MPH, MCHES (1)  ·  Amy L Drapalski, PhD (1)  ·  Anas Younes, MD (1)  ·  Andre Strydom, Prof. (1)  ·  Annis Fung, Ph.D. (1)  ·  Anselm Crombach, Dipl.-Psych. (1)  ·  Baldwin M Way, Ph.D. (1)  ·  Barbie Zimmerman-Bier, M.D. (1)  ·  Bruce G. Pollock, MD, PhD (1)  ·  Bryan King, MD (1)  ·  Celso Arango, Prof. (1)

Results publications

PMID 27355533, PMID 37811711, PMID 17984842, PMID 18977971, PMID 19487623, PMID 20031032, PMID 20625270, PMID 20673556, PMID 21564523, PMID 21575849, PMID 21702900, PMID 23257314, PMID 24061784, PMID 25062336, PMID 25146492, PMID 25313530, PMID 25468234, PMID 26002873, PMID 27173384, PMID 28744009, PMID 29205343, PMID 29625151, PMID 29859917, PMID 30477544, PMID 30506630, PMID 30999262, PMID 31233321, PMID 31352795, PMID 31414842, PMID 32437738, PMID 32880105, PMID 33234053, PMID 33578648, PMID 33658971, PMID 33823927, PMID 33979314, PMID 34059401, PMID 34504446, PMID 35734582, PMID 36636296, PMID 36870019, PMID 36892916, PMID 37322595, PMID 37445385, PMID 37732619, PMID 37957412, PMID 39649724, PMID 39695323, PMID 40392716, PMID 41129363

NIH funding

2005 (1), 2008 (1), 2018 (1), K23MD015270 (1), KL2RR025754-04 (1), R01AG047146 (1), R01DA017295 (1), R01MH059666 (1), R01MH077596 (1), R21NS043979 (1), R42MH087322 (1), R61AT010604 (1), U54MH066398 (1)